Structure Therapeutics, Inc. (GPCR)
91.07
+2.43
(+2.74%)
USD |
NASDAQ |
Jan 20, 16:00
94.17
+3.10
(+3.40%)
After-Hours: 20:00
Structure Therapeutics Cash from Investing (Quarterly): -49.46M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -2.983B |
| Novo Nordisk A/S | -2.440B |
| Pfizer Inc. | -2.43B |
| Viking Therapeutics, Inc. | 160.02M |
| Dyne Therapeutics, Inc. | -37.96M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -51.05M |
| Cash from Financing (Quarterly) | 56.31M |
| Free Cash Flow | -196.67M |
| Free Cash Flow Per Share (Quarterly) | -0.8996 |
| Free Cash Flow to Equity (Quarterly) | -52.03M |
| Free Cash Flow to Firm (Quarterly) | -52.62M |
| Free Cash Flow Yield | -3.74% |